The best revenge
Inland Valley Daily Bulletin - Ontario,CA,USA
COM Montel Williams is 51, has six-pack abs, a new wife and multiple sclerosis. He's equally fine with all of it. "Living Well," the title of his new book, ...
See all stories on this topic

Biogen drug pipeline makes it a tempting target
International Herald Tribune - France
Another approach, also in final patient testing, uses the cancer drug Rituxan against primary, progressive multiple sclerosis, a condition in which the ...
See all stories on this topic

Massachusetts Mitt Meets Right Wing Romney on Meet the Press
Earthtimes - London,UK
[1994 Senate Debate] Mitt Romney Today: Opposes Federal Funding of Embryonic Stem Cell Research. "For federal dollars I would focus on alternative methods. ...
See all stories on this topic

Elan reaffirms commitment to Tysabri drug
MarketWatch - USA
12 that it has completed its strategic review and will continue its present course as an independent company, Elan has reaffirmed its commitment to TYSABRI ...
See all stories on this topic

BioMS Medical's phase III US multiple sclerosis trial receives ...
Canada NewsWire (press release) - Toronto,Ontario,Canada
(TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has ...
See all stories on this topic

BioMS Medical's phase III US multiple sclerosis trial receives ...
Canada NewsWire (press release) - Toronto,Ontario,Canada
(TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has ...
See all stories on this topic

UPDATE 1-Biogen ends auction with no definitive offers
Reuters - USA
I: Quote, Profile, Research) for Tysabri. Under a change of ownership, Genentech and Elan have the right to buy Biogen's rights to those drugs. ...
See all stories on this topic

BioMS Medical's Pivotal International Multiple Sclerosis Trial Receives Positive Review From Data Safety Monitoring Board
BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that following the meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue MAESTRO-01, its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis.15 Dec 2007

ANP Updated Company Profile
Sydney Morning Herald - Sydney,New South Wales,Australia
$US1.5bn); recent licensing deals with Johnson & Johnson and Bristol Myers Squibb ATL1102. There are currently over 17000 patients on Tysabri ANP's strategy ...
See all stories on this topic